Information Provided By: 
Fly News Breaks for December 9, 2016
RDUS
Dec 9, 2016 | 08:41 EDT
Maxim analyst Jason McCarthy called the newly announced data from Radius Health on a phase 1b study of RAD1901 in breast cancer "disappointing," saying early data from phase I studies suggests that the drug shows a lack of efficacy in the difficult to treat population it is targeting. McCarthy, who continues to believe Radius is overvalued, maintains a Sell rating on the stock.
News For RDUS From the Last 2 Days
There are no results for your query RDUS
